Every round on record, with the sources behind each and the investors on them.
AdvanCell is developing targeted alpha radiotherapies for cancer.
advancell.com.auLinkedInBoston, USA and Brisbane, AustraliaBiotechFounded 2019
2 sources
The company release dates the announcement February 3; BusinessWire’s page was published February 7 but carries a February 3 dateline, so the release’s date wins. Sydney is a dateline, not stated headquarters.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source announces AdvanCell's A$18M Series B funding; no valuation, financing total, headquarters, or other investors are stated.; not on the page it cites, so not applied: date
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $112M | 2025-02-03 | SV Health Investors, Sanofi Ventures, Abingworth, SymBiosis | No recent discussion |
2 sources [ VERIFIED · CORRECTED ] read against 2 sources
The company release dates the announcement February 3; BusinessWire’s page was published February 7 but carries a February 3 dateline, so the release’s date wins. Sydney is a dateline, not stated headquarters. | ||||
AdvanCell develops targeted alpha-radiation cancer medicines and the isotope-production and manufacturing systems needed to make them, for patients with hard-to-treat cancers.
Checked against 8 sources today
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $12.4M A$18M | 2022-08-23 | Morningside Group | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The source announces AdvanCell's A$18M Series B funding; no valuation, financing total, headquarters, or other investors are stated.; not on the page it cites, so not applied: date [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: advancell.com.au·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
Also named as backers in company research: Ally Bridge Group, Alpha Wave, Bain Capital Life Sciences, Fidelity Management & Research Company, Eli Lilly and Company, NSW Health Medical Devices Fund, Federal Government Research & Development Tax Incentive